<DOC>
	<DOCNO>NCT01523782</DOCNO>
	<brief_summary>There clinical validation benefit L-asparaginase offer induction chemotherapy elderly patient , prevent toxicity critical.This Phase IIa clinical trial propose evaluate , specifically elderly patient , tolerate dose GRASPA® combination poly chemotherapy treatment enable efficient L-asparagine depletion period least equal 7 day .</brief_summary>
	<brief_title>Administration GRASPA ( Suspension Erythrocytes Encapsulating L-asparaginase ) Elderly Patients With First Line Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Aged ≥ 55 year Newly diagnose ALL without prior treatment Patient capable receive polychemotherapy ( WHO &lt; 2 ) With without meningeal disease Signed Informed Consent Forms Subscribed social security insurance ALL ( 9 ; 22 ) and/or BCRABL positive General state incompatible chemotherapy treatment ( WHO &gt; 2 ) Presenting general visceral contraindication intensive treatment Patient another cancer ALL Severe evolutive infection , , HIV seropositive , active hepatitis relate B C viral infection Prior treatment Lasparaginase ( irrespective form ) History Grade 3 Transfusional incident ( life threaten ) Presenting rare and/or dangerous antierythrocyte antibody thus lead unavailable phenotype compatible Red Blood Cells Included another clinical trial last 4weeks .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Acute Lymphoblastic leukemia</keyword>
	<keyword>Elderly patient</keyword>
	<keyword>Asparaginase</keyword>
</DOC>